Biomarkers predictive of cancer cell response to ML329 or a derivative thereof

Patent metadata

Field	Value
Publication number	US-12560609-B2
Application number	US-201917294475-A
Country	US
Kind code	B2
Filing date	Nov 25, 2019
Priority date	Nov 26, 2018
Publication date	Feb 24, 2026
Grant date	Feb 24, 2026

Abstract

The present invention is based in part on the identification of biomarkers, including NQO1, NRF2 and KEAP1, predictive of cancer cell responsiveness to treatment with ML 329 or a derivative thereof.

First claim

What is claimed is:

1 . A method of treating a cancer in a subject likely to be responsive to 4-[(1,4-dioxo-1,4-dihydronapthalen-2-yl)amino]benzenesulfonamide (ML329) or an ML329 derivative selected from:

the method comprising:
i) selecting the subject likely to be responsive to ML329 or the ML329 derivative, the subject having been identified by
determining the presence of a KEAP1 loss-of-function mutation in cancer cells from the subject

wherein the presence of the kelch-like ECH-associated protein 1 (KEAP1) loss-of-function mutation identifies the subject as likely to be responsive to ML329 or the ML329 derivative; and
ii) administering ML329 or the ML329 derivative to the selected subject.

2 . The method of claim 1 , wherein the subject's cancer cells have KEAP1 loss-of-function.

3 . The method of claim 1 , wherein the KEAP1 loss-of-function mutation is a coding region mutation.

4 . The method of claim 1 , wherein the cancer is selected from the group consisting of melanoma, lung cancer, head and neck squamous cell carcinomas, kidney cancer, pancreas cancer, prostate cancer, bladder cancer, uterine cancer, head and neck cancer, and esophagus cancer.

5 . The method of claim 1 , wherein the subject is likely to be responsive to ML329 and the method comprises administering ML329 to the selected subject.

6 . The method of claim 1 , wherein the subject is likely to be responsive to the ML329 derivative, SCAP105461, and the method comprises administering SCAP105461 to the selected subject.

7 . The method of claim 1 , wherein the subject is likely to be responsive to the ML329 derivative, SCAP105463, and the method comprises administering SCAP105463 to the selected subject.

8 . The method of claim 1 , wherein the subject is
a) an animal model of cancer; b) a mammal; c) a mouse; or d) a human.

9 . The method of claim 1 , wherein the cancer is a lung cancer.

10 . The method of claim 5 , wherein the cancer is a lung cancer.

11 . The method of claim 6 , wherein the cancer is a lung cancer.

12 . The method of claim 7 , wherein the cancer is a lung cancer.

Assignees

• Dana Farber Cancer Inst Inc
• Massachusetts Gen Hospital
• Univ Kansas

Inventors

• Haq Rizwan
• Fisher David
• Schoenen Frank

Classifications

• G01N2333/90209

  acting on NADH or NADPH (1.6), e.g. those with a heme protein as acceptor (1.6.2) (general), Cytochrome-b5 reductase (1.6.2.2) or NADPH-cytochrome P450 reductase (1.6.2.4) · CPC title

• G01N33/6875

  Nucleoproteins · CPC title

• A61K31/18

  Sulfonamides (compounds containing a para-N-benzene-sulfonyl-N- group A61K31/63) · CPC title

• G01N33/575 Primary

  for cancer · CPC title

• G01N33/5014

  for testing toxicity · CPC title